About Semaglutide
            
            Class: | GLP-1 receptor agonist  
Use: | Indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity  
Adult dose: | Initial dose of 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly; may be increased to 1 mg after 4 weeks based on tolerance and efficacy  
Pediatric dose: | Safety and efficacy not established in pediatric patients under 18 years  
Side effects: | Nausea, vomiting, diarrhea, const
         
        
            
                
                
                    
                        Drug Class
                    
                    GLP-1 receptor agonist
                 
                
                
                    
                        Uses & Indications
                    
                    Indicated for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator (36°F to 46°F or 2°C to 8°C); may be stored at room temperature (up to 86°F or 30°C) for up to 28 days after first use
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: NOVO NORDISK A/S [Bagsvaerd;Denmark], Denmark
                    
                    
                    Package Size
                    1.5mL Prefilled Pen  + 4 Disposable NovoFine Plus Needles (4 Doses)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 743.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose of 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly; may be increased to 1 mg after 4 weeks based on tolerance and efficacy
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients under 18 years
                    
                 
                
                
                    
                        Side Effects
                    
                    Nausea, vomiting, diarrhea, constipation, abdominal pain, headache
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), hypersensitivity to semaglutide or any component of the formulation
         
        
        
            
                Important Warnings
            
            Risk of thyroid C-cell tumors; pancreatitis; renal impairment; hypoglycemia when used with insulin or sulfonylureas; not recommended for use in patients with a history of severe gastrointestinal disease
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.